Inhalation profiles in asthmatics and COPD patients: Reproducibility and effect of instruction

Journal of Aerosol Medicine: Deposition, Clearance, and Effects in the Lung

Volumn 16, Issue 2, 2003, Pages 131-141

  Broeders, Mariëlle E A C ^a   Molema, Johan ^a   Hop, Wim C J ^b   Folgering, Hans T M ^a  

^a RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

DPI; Inhalation profile; Inhalation therapy; Instruction; pMDI; Reproducibility

Indexed keywords

FLUTICASONE; SALBUTAMOL;

ADULT; AEROSOL; AGED; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; FEMALE; FLOW RATE; HUMAN; INHALATION; INSPIRATORY CAPACITY; INTERMETHOD COMPARISON; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; PEAK EXPIRATORY FLOW; PEAK INSPIRATORY FLOW; REPRODUCIBILITY; TIME SERIES ANALYSIS;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; AGED; ALBUTEROL; ASTHMA; FEMALE; HUMANS; MALE; MIDDLE AGED; MOTOR SKILLS; NEBULIZERS AND VAPORIZERS; PATIENT EDUCATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REPRODUCIBILITY OF RESULTS; RESPIRATORY MECHANICS; STATISTICS, NONPARAMETRIC;

EID: 0038808970     PISSN: 08942684     EISSN: None     Source Type: Journal    
DOI: 10.1089/089426803321919898     Document Type: Article

References (35)

1. Pauwels, R., S. Newman, and L. Borgstrom. 1997. Airway deposition and airway effects of antiasthma drugs delivered from metered-dose inhalers. Eur. Respir. J. 10:2127-2138.
2. Goodman, D.E., E. Israel, M. Rosenberg, et al. 1994. The influence of age, diagnosis, and gender on proper use of metered-dose inhalers. Am. J. Respir. Crit. Care Med. 150:1256-1261.
3. Selroos, O., A. Pietinhalho, and H. Riska. 1996. Delivery devices for inhaled asthma medication. Clinical implications of differences in effectiveness. Clin. Immunother. 6:273-299.
4. Ganderton, D. 1997. General factors influencing drug delivery to the lung. Respir. Med. 91:13-16.
5. Malton, A., B.S. Sumby, and Y. Dandiker. 1996. A comparison of in vitro drug delivery from salbutamol Diskus and terbutaline Turbohaler inhaler. J. Pharm. Med. 6:35-48.
6. de Boer, A.H., D. Gjaltema, and P. Hagedoom. 1996. Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers. Part 2: Effect of peak flow rate (PIFR) and inspiration time on the in vitro drug release from three different types of commercial dry powder inhalers. Int. J. Pharm. 138: 45-56.
7. Clark, A.R., and A.M. Hollingworth. 1993. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers - implications for in vitro testing. J. Aerosol Med. 6:99-110.
8. de Boer, A.H., H.M.I. Winter, and C.F. Lerk. 1996. Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers. Part 1. Inhalation characteristics, work of breathing and volunteers'preference in dependence of the inhaler resistance. Int. J. Pharm. 130:231-244.
9. Everard, M.L., S.G. Devadason, and P.N. Le Souef. 1997. Flow early in the inspiratory manoeuvre affects the aerosol particle size distribution from a Turbuhaler. Respir. Med. 91:624-628.
10. Newhouse, M.T. 1982. Principles of aerosol therapy. Chest 82:39S-41S.
11. Carveth, H.C., and R.E. Kanner. 1999. Optimizing deposition of aerosolized drug in the lung: a review. Medscape Respir. Care 3.
12. Nielsen, K.G., I.L. Auk, K. Bojsen, et al. 1998. Clinical effect of Diskus dry-powder inhaler at low and high inspiratory flow-rates in asthmatic children. Eur. Respir. J. 11:350-354.
13. Bisgaard, H., B. Klug, B.S. Sumby, et al. 1998. Fine particle mass from the Diskus inhaler and Turbuhaler inhaler in children with asthma. Eur. Respir. J. 11: 1111-1115.
14. Brindley, A., P.W. Barry, B.S. Sumby, et al. 1995. Design, manufacture and dose consistency of the serevent diskus inhaler. Pharm. Tech. Eur. 7:14-22.
15. Fuller, R. 1995. The Diskus: a new multi-dose powder device - efficacy and comparison with Turbuhaler. J. Aerosol. Med. 8(Suppl 2):S11-S17.
16. Newman, S.P., F. Moren, N. Talaee, et al. 1991. Terbutaline sulphate Turbuhaler: effect of inhaled flow rate on drug deposition and efficacy. Int. J. Pharm. 74: 209-213.
17. Engel, T., J.H. Heinig, F. Madsen, et al. 1990. Peak inspiratory flow and inspiratory vital capacity of patients with asthma measured with and without a new dry-powder inhaler device (Turbuhaler). Eur. Respir. J. 3:1037-1041.
18. Siafakas, N.M., P. Vermeire, N.B. Pride, et al. 1995. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur. Respir. J. 8: 1398-1420.
19. Wilson, S.H., N.T. Cooke, R.H. Edwards, et al. 1984. Predicted normal values for maximal respiratory pressures in caucasian adults and children. Thorax 39:535-538.
20. Bisgaard, H. 1997. Delivery of inhaled medication to children. J. Asthma. 34:443-467.
21. Bisgaard, H., O'Callaghan, C., and Smaldone, G.C. 2002. New York, Marcel Dekker. Drug Delivery to the Lung.
22. de Boer, A.H. 1999. Poeder-inhalatoren in de praktijk: technologische aspecten en instructie voor gebruik. Maarsen, Elsevier.
23. Arvidsson, P., A. Mellen, M. Palmqvist, et al. 2000. Equivalent therapeutic ratio of salbutamol given by Turbuhaler and Diskus. Respir. Med. 94:574-577.
24. Cochrane, M.C., M.V. Bala, K.E. Downs, et al. 2000. Inhaled corticosteroids for asthma therapy. Patients compliance, devices and inhalation technique. Chest 117:542-550.
25. Larsen, J.S., M. Hahn, B. Ekholm, et al. 1994. Evaluation of conventional press-and-breathe metered-dose inhaler technique in 501 patients. J. Asthma 31:193-199.
26. Horsley, M.G., and G.R. Bailie. 1988. Risk factors for inadequate use of pressurized aerosol inhalers. J. Clin. Pharm. Ther. 13:139-143.
27. van der Palen, J., J.J. Klein, A.H. Kerkhoff, et al. 1997. Evaluation of the long-term effectiveness of three instruction modes for inhaling medicines. Patient. Educ. Couns. 32:S87-S95.
28. Newman, S.P., A.W. Weisz, N. Talaee, et al. 1991. Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique. Thorax 46:712-716.
29. Hughes, D.A., A. Woodcock, and T. Walley. 1999. Review of therapeutically equivalent alternatives to short-acting beta2 adrenoceptor agonists delivered via chlorofluorocarbon-containing inhalers. Thorax 54: 1087-1092.
30. Leach, C.L., P.J. Davidson, and R.J. Boudreau. 1998. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur. Respir. J. 12:1346-1353.
31. Chrystyn, H. 1999. The Diskus Inhaler: a review of its pharmaceutical and clinical performance. Clin. Drug Invest. 18:287-296.
32. Dewar, M.H., A. Jamieson, A. McLean, et al. 1999. Peak inspiratory flow through Turbuhaler in chronic obstructive airways disease. Respir. Med. 93:342-344.
33. Hawksworth, G.M., L. James, and H. Chrystyn. 2000. Characterization of the inspiratory manoeuvre when astmatics inhale through a Turbohaler pre- and postcounselling in a community pharmacy. Respir. Med. 94:501-504.
34. Stevens, S.S. 1975. Psychophysics: introduction to its perceptual, neural and social prospects. New York, Wiley.
35. Svartengren, K., P. Lindestad, M. Svartengren, et al. 1995. Added external resistance reduces oropharyngeal deposition and increases lung deposition of aerosol particles in asthmatics. Am. J. Respir. Crit. Care Med. 152:32-37.